Valeant (NYSE:VRX) is raring to deliver what Mizuho’s Irina Rivkind Koffler expects will be a solid second quarter print, with the potential for a …
Shares of Valeant (NYSE:VRX) sold off recently after the FDA gave a no-go to the company’s plaque psoriasis treatment Duobrii. The FDA’s issuance of …
After June, you won’t have Valeant (NYSE:VRX) to kick around anymore. The Canada-based drug company will be changing its name to Bausch Health Companies, …
Valeant Pharmaceuticals (NYSE:VRX) wholly owned subsidiary Salix and US WorldMeds announced today that they have entered into an exclusive agreement to co-promote US WorldMeds’ LUCEMYRA™ …
Valeant (NYSE:VRX) shares fell 12% yesterday on news that the FDA issued a complete response letter (CRL) concerning the drug maker’s plaque psoriasis …
Looking for a reason to buy shares of Valeant? How about three reasons, courtesy of Cantor analyst Louise Chen.
Valeant (NYSE:VRX) shares are dipping 6% in early trading Monday, after the drug maker announced that it has received a Complete Response Letter (CRL) …
H.C.
While Valeant shows signs of a rebound, RBC Capital’s Douglas Miehm remains sidelined.
On back of a solid swing for VRX’s rebounding momentum, BTIG’s Tim Chiang sheds light on Q1 earnings and a forthcoming name change.